Tim Haines serves as Chairman and Managing Partner at Abingworth, a London-based venture capital firm. See sector focus and contact routes.
Tim Haines serves as Chairman and Managing Partner at Abingworth, a London-based venture capital firm, with over 30 years of international management experience in the life sciences industry across public and private companies[1]. He joined Abingworth in 2005 after leading portfolio company Astex Therapeutics as its Chief Executive for more than five years, where he helped establish it as a leading UK biotechnology firm[1]. Abingworth’s investment focus centers on life sciences, including biotechs and CNS diseases, with prior investments in companies like Alnylam and CRISPR Therapeutics[5]. While specific check sizes and lead/follow behavior for Haines are not publicly detailed, he has held chair and board roles in numerous Abingworth investments including Astex, GammaDelta Therapeutics, and MEDIAN Technologies[1]. Notable portfolio companies associated with his tenure include Astex Therapeutics, CRISPR Therapeutics, and Alnylam[1][5]. Haines also contributes to the broader ecosystem as a member of Oxford University Innovation’s Investment Advisory Board and formerly served on the BVCA Venture Committee and the Wellcome Trust/NHS Health Innovation Challenge Fund[1].
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in London when building a target list.
Investors like Tim Haines · Full investor directory · Investor access · Company funding database